UK Health Minister Abandons Plan for Smoke-Free 2030

Dec.13.2022
UK Health Minister Abandons Plan for Smoke-Free 2030
UK Health Minister cancels plan to make country smoke-free by 2030, keeping legal tobacco buying age at 18.

Health Minister Steve Barclay has announced the cancellation of a plan to make the country smoke-free by 2030, ending hopes of saving an additional 500,000 lives.


Sources from the White House have reported that they are abandoning plans to raise the legal age for tobacco purchases by one year each year until no one can purchase cigarettes.


This means that the minimum legal age for tobacco sales will remain at 18 years old. Anti-smoking activists argue that this is a missed opportunity to reduce smoking rates among young people by one-third.


Smoking is unlikely to be abandoned as a public health issue by any responsible government aiming for a smoke-free future by 2030, according to Deborah Arnott of the Action on Smoking and Health organization.


This is a government in the final stages that clearly lacks imagination and has lost its courage.


Former Minister of Health, Saeed Javed's goal was to lower the proportion of smokers in the population from over 13% to 5% within seven years, effectively defining a smoke-free target.


He commissioned Dr. Javed Khan, former head of the Barnardo's charity, to publish a report in June to fulfill the Conservative Party's 2019 manifesto promise of extending life expectancy by five years by 2035.


Dr. Khan stated that the government will only achieve its smoke-free goal within seven years if his measures are implemented.


He also hopes to see ministers invest £125 million to help people quit smoking, prescribe e-cigarettes, and ban outdoor smoking in areas where children gather.


Mr. Khan added, "We need to make smoking as difficult as possible and make quitting as easy as possible.


These intervention measures are crucial. There are no shortcuts, no quick fixes, and no excuses.


David Buck, from the King's Fund health think tank, commented on changes in age demographics, stating: "This is a very intelligent proposal. It can assist individuals, manufacturers, and retailers in planning for long-term changes.


Ms. Arnott supports raising the age limit to 21 years old. She claims that this measure would decrease smoking rates in the age group of 18-21 by 30%.


Smoking leads to 75,000 deaths each year in England and costs the NHS £2.4 billion.


Bob Blackman, the chairman of the All-Party Parliamentary Group on Smoking and Health and a Conservative MP, has stated that downplaying the UK's tobacco strategy could have adverse effects on reducing NHS waiting lists.


The number of deaths caused by tobacco is 30 times higher than the number of deaths caused by smoking-related illnesses.


Even though the Health Secretary Neil O'Brien told Members of Parliament 12 days ago that "we are considering the potential benefits of raising the age at which tobacco products can be sold, but age increase has been cancelled.


A spokesperson for the Department of Health and Social Care (DHSC) stated, "We are currently considering the extensive suggestions put forth in Khan's remarks.


2FIRSTS will continue to cover this topic and provide ongoing updates on the "2FIRSTS APP." Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Earnings Analysis | CTIHK H1 2026 Revenue Falls 26.9% as Core Businesses Diverge and New Growth Drivers Remain to Be Proven
Earnings Analysis | CTIHK H1 2026 Revenue Falls 26.9% as Core Businesses Diverge and New Growth Drivers Remain to Be Proven
China Tobacco International (HK) reported a 26.9% revenue decline in H1 2026, while gross profit fell only 9.5%, revealing sharp divergence across its businesses. Tobacco leaf imports contracted, while leaf exports and Brazil operations expanded strongly. Cigarette exports faced China duty-free market transition, and new tobacco products remained small. Meanwhile, CTIHK continues to strengthen its role as an investment and financing platform, though major external deals have yet to emerge. 2Firsts examines what these shifts mean for its next growth drivers.
Capital Markets
Aug.24
2Firsts Hosts U.S. Market Mid-Year Briefing: Companies Need to Reassess Product and Market-Access Strategies
2Firsts Hosts U.S. Market Mid-Year Briefing: Companies Need to Reassess Product and Market-Access Strategies
2Firsts held its 2026 U.S. Market Compliance and Development Mid-Year Briefing in Shenzhen, China, on July 28. The discussion examined how state-level requirements, proposed foreign-establishment registration rules and expanding supply-chain responsibilities are changing product and investment decisions in the U.S. tobacco and nicotine market.
Jul.29
China’s Jiangsu Tobacco Monopoly Bureau and Drug Regulator Target Illegal Vape Sales Disguised as Medical Devices, Define Six Violations
China’s Jiangsu Tobacco Monopoly Bureau and Drug Regulator Target Illegal Vape Sales Disguised as Medical Devices, Define Six Violations
China’s Jiangsu Tobacco Monopoly Bureau and Jiangsu Provincial Medical Products Administration have issued a joint notice targeting illegal production and sales of vape products disguised as medical devices. The notice identifies six categories of violations, including obtaining medical licenses through false materials, misusing medical device credentials, expanding production beyond approved scopes, and using medical device-related online platforms to promote or sell vape products. The action is based on China’s tobacco and medical device regulations and aims to strengthen vape oversight and consumer protection.
Aug.04
IVG Parent Secures HMRC Excise Warehouse and Duty Stamp Approvals Ahead of UK Vape Tax
IVG Parent Secures HMRC Excise Warehouse and Duty Stamp Approvals Ahead of UK Vape Tax
Acme Vape Ltd, the company behind UK vaping brand IVG, has received HM Revenue & Customs approval to operate an excise warehouse for vaping products and participate in the Vaping Duty Stamps Scheme. The UK's Vaping Products Duty will take effect on October 1, 2026, at a flat rate of £2.20 per 10ml of vaping liquid. Acme Vape Ltd says its approved warehouse in Preston will become operational under the new regime on the same date.
Regulations
Sep.18 by 2Firsts Perspectives
Ireland’s Vape Tax Raises €22 Million in Nine Months as Government Considers 2027 Budget Changes
Ireland’s Vape Tax Raises €22 Million in Nine Months as Government Considers 2027 Budget Changes
According to Irish media outlets Highland Radio and BreakingNews.ie, the Irish government is considering whether to adjust vape tax policy in the 2027 Budget. The tax has generated about €22 million ($24 million) in revenue during its first nine months. While no increase has been confirmed, the revenue performance could influence future fiscal discussions. Any tax rise could increase product costs and potentially affect retail prices.
Aug.12
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22